Acer Therapeutics Inc
F:P6NA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Acer Therapeutics Inc
Selling, General & Administrative
Acer Therapeutics Inc
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Acer Therapeutics Inc
F:P6NA
|
Selling, General & Administrative
-$12.7m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-18%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Selling, General & Administrative
-$24.6B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Selling, General & Administrative
-$7.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-4%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Selling, General & Administrative
-$13.6B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Selling, General & Administrative
-$10.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-1%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Selling, General & Administrative
-$11.1B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-5%
|
|
Acer Therapeutics Inc
Glance View
Acer Therapeutics, Inc. is a pharmaceutical company. The company is headquartered in Newton, Massachusetts and currently employs 35 full-time employees. The company went IPO on 2006-09-01. The Company’s pipeline includes four programs: ACER-001 (sodium phenylbutyrate), ACER-801 (osanetant), EDSIVO (celiprolol) and ACER-2820 (emetine). ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); ACER-801 (osanetant) for the treatment of induced vasomotor symptoms (iVMS); EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and ACER-2820 (emetine), a host-directed therapy against a variety of viruses, including cytomegalovirus, zika, dengue, ebola and COVID-19.
See Also
What is Acer Therapeutics Inc's Selling, General & Administrative?
Selling, General & Administrative
-12.7m
USD
Based on the financial report for Dec 31, 2022, Acer Therapeutics Inc's Selling, General & Administrative amounts to -12.7m USD.
What is Acer Therapeutics Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-18%
Over the last year, the Selling, General & Administrative growth was -19%. The average annual Selling, General & Administrative growth rates for Acer Therapeutics Inc have been 8% over the past three years , -19% over the past five years , and -18% over the past ten years .
